Rotman Harris 4
4 · Centessa Pharmaceuticals plc · Filed Sep 22, 2023
Insider Transaction Report
Form 4
Rotman Harris
SVP Regulatory Affairs
Transactions
- Sale
Ordinary Shares
2023-09-20$6.29/sh−37,484$235,688→ 33,500 total - Exercise/Conversion
Share Option (right to buy)
2023-09-20−31,250→ 93,750 totalExercise: $4.47Exp: 2032-08-01→ Ordinary Shares (31,250 underlying) - Exercise/Conversion
Ordinary Shares
2023-09-20$4.47/sh+31,250$139,688→ 64,750 total - Exercise/Conversion
Ordinary Shares
2023-09-20$3.85/sh+6,234$24,001→ 70,984 total - Exercise/Conversion
Share Option (right to buy)
2023-09-20−6,234→ 43,666 totalExercise: $3.85Exp: 2033-02-01→ Ordinary Shares (6,234 underlying)
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2023.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]25% of the shares subject to such option shall vest and become exercisable on August 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
- [F5]6,234 of the shares vest and become exercisable on August 1, 2023 and 1/48th of the shares subject to such option shall vest and become exercisable in 42 monthly installments on the first day of each month thereafter.